Analysts Set Progyny, Inc. (NASDAQ:PGNY) Target Price at $48.30

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) has been given an average rating of "Buy" by the ten research firms that are covering the company, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $48.30.

Several research firms recently weighed in on PGNY. Barclays began coverage on shares of Progyny in a research note on Wednesday, January 3rd. They set an "overweight" rating and a $48.00 price objective on the stock. KeyCorp cut their price target on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating on the stock in a report on Wednesday, February 28th. Truist Financial cut their price target on shares of Progyny from $47.00 to $46.00 and set a "buy" rating on the stock in a report on Wednesday, February 28th. Leerink Partnrs reiterated an "outperform" rating on shares of Progyny in a report on Monday, February 26th. Finally, SVB Leerink began coverage on shares of Progyny in a report on Monday, February 26th. They issued an "outperform" rating and a $49.00 target price on the stock.

Progyny Trading Down 0.7 %

NASDAQ:PGNY traded down $0.25 on Thursday, reaching $35.50. The stock had a trading volume of 540,272 shares, compared to its average volume of 812,158. The company has a 50-day moving average of $37.81 and a 200 day moving average of $35.65. The stock has a market cap of $3.43 billion, a P/E ratio of 57.66, a price-to-earnings-growth ratio of 1.47 and a beta of 1.48. Progyny has a 12-month low of $29.44 and a 12-month high of $44.95.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business had revenue of $269.94 million for the quarter, compared to analysts' expectations of $274.08 million. During the same quarter last year, the company posted $0.03 earnings per share. The company's quarterly revenue was up 26.0% compared to the same quarter last year. On average, equities analysts predict that Progyny will post 0.7 EPS for the current year.

Insider Activity at Progyny

In other Progyny news, CFO Mark S. Livingston sold 11,165 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $37.62, for a total value of $420,027.30. Following the sale, the chief financial officer now directly owns 50,119 shares in the company, valued at $1,885,476.78. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Chairman David J. Schlanger sold 20,000 shares of the firm's stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the sale, the chairman now owns 86,312 shares in the company, valued at approximately $3,323,012. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Mark S. Livingston sold 11,165 shares of the firm's stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.62, for a total transaction of $420,027.30. Following the sale, the chief financial officer now owns 50,119 shares of the company's stock, valued at approximately $1,885,476.78. The disclosure for this sale can be found here. Insiders have sold 186,517 shares of company stock worth $7,070,287 over the last ninety days. Company insiders own 14.30% of the company's stock.

Institutional Trading of Progyny

Hedge funds and other institutional investors have recently bought and sold shares of the business. RiverPark Advisors LLC grew its holdings in shares of Progyny by 54.0% during the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company's stock valued at $40,000 after purchasing an additional 374 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Progyny in the 1st quarter valued at approximately $62,000. Parkside Financial Bank & Trust bought a new position in shares of Progyny during the first quarter valued at $70,000. Acadian Asset Management LLC bought a new position in shares of Progyny during the third quarter valued at $53,000. Finally, International Assets Investment Management LLC acquired a new position in Progyny during the 3rd quarter worth about $58,000. Institutional investors and hedge funds own 94.93% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.